AmericanPeptide
Catalog/Cortagen

Cortagen

Also known as Ala-Glu-Asp-Pro · AEDP

A Khavinson short peptide bioregulator (Ala-Glu-Asp-Pro) studied for cerebral-cortex and peripheral-nerve regeneration.

Research refreshed

Primary structure

AEDP

4 residues · single-letter amino-acid sequence

Overview

Cortagen is one of the Khavinson short-peptide bioregulators — a synthetic tetrapeptide, Ala-Glu-Asp-Pro, developed in Russia and associated with the cerebral cortex and nervous tissue. Like the other bioregulators in this family, it is proposed to act as a tissue-specific, gene-regulatory signal, and it has been studied in Russian research for peripheral-nerve repair and CNS function. It is a research peptide, and its evidence base is largely from one research school and is not FDA-approved.

Background

Cortagen belongs to the family of short peptide bioregulators developed by Khavinson and colleagues, each linked to a particular tissue — Cortagen to the cerebral cortex and nervous system. The governing idea is that very short peptides act as regulatory signals that normalize gene expression and function in their target tissue, and this catalog profiles several members (Cartalax, Pinealon, Cerluten, and others) on the same premise.

Research on Cortagen, mainly from Russian groups, has examined peripheral-nerve regeneration and cortical function. As with the family generally, independent replication is limited and the mechanism remains a hypothesis rather than an established pathway. It is a research compound and is not FDA-approved; this page is a research and educational reference.

Mechanism

Proposed tissue-specific gene-regulatory activity (the Khavinson bioregulator hypothesis): short peptides binding DNA/chromatin to modulate expression in cortical and neural tissue. Mechanism is hypothesized more than proven in independent work.

Key research findings

  • Cortex bioregulator — a Khavinson tetrapeptide (Ala-Glu-Asp-Pro) associated with the cerebral cortex and nervous tissue.
  • Nerve-regeneration research — studied in peripheral-nerve-repair models.
  • Gene-regulatory hypothesis — proposed to act as a tissue-specific regulator, like the rest of the bioregulator family.
  • Limited independent evidence — mainly single-school research; not FDA-approved.

How Cortagen is made

Behind every vial of Cortagen is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Cortagen, specifically, is brought into being.

  1. On paper first

    Cortagen begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.

  2. Built residue by residue

    Assembling Cortagen means roughly 4 coupling cycles on the synthesizer — one protected residue added at a time, which is also 4 chances for an incomplete coupling to seed a deletion impurity. It is a short sequence, which makes the build comparatively tractable — but short does not mean trivial, and purity is still won or lost downstream.

  3. Purity is won here

    The crude mixture — Cortagen plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.

  4. Proven, then protected

    A real batch of Cortagen proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Cortagen — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.

Walk the full synthesis pipeline

Handling, storage & why purity is hard

A linear tetrapeptide (Ala-Glu-Asp-Pro) — trivial to synthesize by solid-phase methods. Making it is easy; the real question is identity, because a 4-mer is cheap to produce under any label. A certificate should show mass spectrometry and HPLC assay confirming the exact sequence and purity.

Standard synthesis
Storage
Store lyophilized, frozen, and protected from light; refrigerate reconstituted peptide for short-term use. A tetrapeptide is physically simple but still degrades in solution over time.
Handling
Reconstitute gently. Because a 4-mer is trivial to produce under any label, the meaningful check is identity — mass spectrometry confirming the exact Ala-Glu-Asp-Pro sequence.

Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.

How peptides are made — the full pipeline

Research areas

  • Peripheral-nerve regeneration
  • Cerebral-cortex function
  • Peptide bioregulator research

Research-area guides

Latest research

Recent clinical trials and publications mentioning Cortagen, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.

Frequently asked questions

What is Cortagen?+

A Khavinson short-peptide bioregulator (Ala-Glu-Asp-Pro) associated with the cerebral cortex and nervous tissue, studied for nerve regeneration and cortical function.

How is it thought to work?+

Through the bioregulator hypothesis — short peptides acting as tissue-specific, gene-regulatory signals. The mechanism is hypothesized more than independently proven.

How strong is the evidence?+

Limited and largely from one research tradition, with little independent replication. Treat it as an early research compound.

Is it approved?+

No — it is a research peptide, not FDA-approved. This page is a research and educational reference.

Related peptides

Peptide Agent

Ask the Agent about Cortagen

Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.